Werewolf Therapeutics Inc (NAS:HOWL) Stock News, Headlines & Updates
Werewolf Therapeutics Inc Stock News from GuruFocus
- 1
Jul 09, 2025
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Marketwired • 7:00am
Jun 12, 2025
Werewolf Therapeutics to Participate in the BIO International Convention
Marketwired • 7:00am
May 29, 2025
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Marketwired • 7:00am
May 27, 2025
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News
GuruFocus News • 6:46am
May 20, 2025
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2
GuruFocus News • 3:21pm
May 13, 2025
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
Marketwired • 7:00am
May 09, 2025
Wedbush Adjusts Price Target on WEREWOLF THERAPEUTICS (HOWL) to USD 6.00 | HOWL Stock News
GuruFocus News • 12:31pm
Wedbush Adjusts Price Target for Werewolf Therapeutics (HOWL) Following Stock Decline | HOWL Stock News
GuruFocus News • 8:15am
May 08, 2025
Werewolf Therapeutics (HOWL) Advances Clinical Trials and Expands Educational Initiatives | HOWL Stock News
GuruFocus News • 7:30am
Werewolf Therapeutics Inc (HOWL) Q1 2025 Earnings: EPS of -$0.40 Beats Estimates, No Revenue Reported, Missing $0.30 Million Estimate
GuruFocus News • 6:42am
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Marketwired • 6:00am
May 05, 2025
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD)Â at AAI Annual Meeting
Marketwired • 8:00am
Werewolf Therapeutics (HOWL) Showcases Innovative IBD Treatment Developments | HOWL Stock News
GuruFocus News • 7:31am
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD)Â at AAI Annual Meeting | HOWL Stoc
GuruFocus News • 7:17am
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Marketwired • 7:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news